Hipias de Elis (o de Élide) fue un pensador del siglo V a. C. que encarnó como pocos el ideal del polímata: el sabio capaz de dominar múltiples disciplinas. Matemático, filósofo, astrónomo, lingüista y diplomático, Hipias fue uno de los so …
Hipias de Elis: el sabio total de la Grecia clásica que quiso saberlo todo Read More »
Las células madre se han convertido en uno de los pilares más prometedores de la medicina moderna. Capaces de regenerar tejidos, reparar órganos dañados y abrir nuevas vías terapéuticas para enfermedades hasta ahora incurables, su estudio ha pasado del labor …
El envejecimiento es un proceso biológico inevitable, pero no siempre avanza al mismo ritmo para todas las personas. Cada vez más estudios científicos apuntan a un fenómeno inquietante: quienes asumen grandes responsabilidades de forma prolongada —líderes emp …
In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace takes a deep dive into which companies and locations were impacted and speaks to experts about what to expect ahead—and why.
Biopharmas Axed 47% More Employees Year Over Year Read More »
The China-based surgical robot manufacturer is gearing up for growth after receiving Europe’s CE mark last year for its single port endoscopic system.
Surgerii Robotics raises $100M to fund global expansion Read More »
The change runs counter to the company’s broader efforts to pare back red tape for physicians amid widespread discontent with health insurers.
UnitedHealthcare raises bar for doctors to get paid for radiology services Read More »
Johnson & Johnson’s filing comes a month after Medtronic gained U.S. clearance for its Hugo system as competition in the soft tissue robotic surgery market heats up.
J&J submits FDA de novo request for Ottava robot in general surgery Read More »
Piecemeal extensions of Medicare coverage for virtual services have impeded access to care, the American Medical Association argued. The policies could expire again on Jan. 30.
Provider, telehealth groups urge Congress to make telehealth flexibilities permanent Read More »
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money Read More »
The cardiovascular biotech was also named as one of BioSpace’s top startups to watch on Wednesday.
Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic Read More »
